{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(3)"],"submitter":["Martinho O"],"pubmed_abstract":["Persistent HPV infection alone is not sufficient for cervical cancer development, which requires additional molecular alterations for tumor progression and metastasis ultimately leading to a lethal disease. In this study, we performed a comprehensive analysis of HER family receptor alterations in cervical adenocarcinoma. We detected overexpression of HER protein, mainly HER2, which was an independent prognostic marker for these patients. By using <i>in vitro</i> and <i>in vivo</i> approaches, we provided evidence that HER inhibitors, allitinib and lapatinib, were effective in reducing cervical cancer aggressiveness. Furthermore, combination of these drugs with glucose uptake blockers could overcome the putative HIF1-α-mediated resistance to HER-targeted therapies. Thus, we propose that the"],"journal":["Theranostics"],"pagination":["717-732"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5327645"],"repository":["biostudies-literature"],"pubmed_title":["HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors."],"pmcid":["PMC5327645"],"pubmed_authors":["Miranda-Goncalves V","Silva-Oliveira R","Zanon M","Reis RM","Scapulatempo-Neto C","Baltazar F","Barbosa AM","Moreira MA","Cury FP","Marques F","Cardoso-Carneiro D","Martinho O","Evangelista AF","de Paula FE","Longatto-Filho A","Granja S"],"additional_accession":[]},"is_claimable":false,"name":"HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.","description":"Persistent HPV infection alone is not sufficient for cervical cancer development, which requires additional molecular alterations for tumor progression and metastasis ultimately leading to a lethal disease. In this study, we performed a comprehensive analysis of HER family receptor alterations in cervical adenocarcinoma. We detected overexpression of HER protein, mainly HER2, which was an independent prognostic marker for these patients. By using <i>in vitro</i> and <i>in vivo</i> approaches, we provided evidence that HER inhibitors, allitinib and lapatinib, were effective in reducing cervical cancer aggressiveness. Furthermore, combination of these drugs with glucose uptake blockers could overcome the putative HIF1-α-mediated resistance to HER-targeted therapies. Thus, we propose that the","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2025-04-04T09:00:24.837Z","creation":"2019-03-27T02:37:26Z"},"accession":"S-EPMC5327645","cross_references":{"pubmed":["28255362"],"doi":["10.7150/thno.17154"]}}